India and Europe Generic Injectable Market - Industry Trends and Forecast to 2035

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	177 Pages	Data Bridge Market Research	January, 2024	DAABD18552228

Best Price Guarantee
Price	from $3,500
Length	177 Pages
Publisher	Data Bridge Market Research
Published Date	January, 2024
SKU	DAABD18552228

India and Europe Generic Injectable Market - Industry Trends and Forecast to 2035

The Europe generic injectable market is expected to reach USD 99,764.84 million by 2035 from USD 36,370.78 million in 2023, growing with a CAGR of 9.0% in the forecast period of 2024 to 2035.
The India generic injectable market is expected to reach USD 19,298.93 million by 2035 from USD 7,128.62 million in 2023, growing with a CAGR of 8.9% in the forecast period of 2024 to 2035.
Market Segmentation
India and Europe Generic Injectable Market, By Therapeutic Application (Oncology, Cardiovascular Disorders, Infectious Diseases, Pain Management, Metabolic Disorders (Diabetes) Immunology Disorders), Biosimilar Drugs (Semaglutide, Ibutidlide Fumarate, Evolocumab, Alirocumab, Anidulafungin, Dulaglutide, Lixisenatide, Exenatide, Liraglutide, and Adalimumab), End User (Direct Sale, Distributors, Pharmaceutical Wholesalers, Drug Stores, Pharmacy, Group Purchasing Organizations(GPOs), and Others), Distribution Channel (Contract Manufacturers, Pharmaceutical Wholesalers, Pharmacy Chains, Group Purchasing Organizations(GPOs), and Others) Country (India) - Industry Trends and Forecast to 2035

Overview of India and Europe Generic Injectable Market Dynamics

Driver
• Surge in the development and production of generic injectable

Restraint

• Ensuring the qualification and ethical standards of a Contract Manufacturing Organization (CMO)

Opportunity

• Market expansion surging with a heightened focus on contract research manufacturing organization

Market Players

Some of the major market players operating in the India and Europe generic injectable market are listed below:

• Fresenius SE & Co. KGaA
• Amneal Pharmaceuticals LLC
• Sun Pharmaceutical Industries Ltd.
• LUPIN.
• Zydus Group
• Aurobindo Pharma.
• Cipla Inc.
• Concord Biotech.
• Dr. Reddy’s Laboratories Ltd.
• Gland Pharma Limited
• GLENMARK PHARMACEUTICALS LTD.
• Hikma Pharmaceticals PLC
• Intas Pharmaceuticals Ltd.
• Par Pharmacetical
• Sandoz Group AG
• Sanofi
• Viatris Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of India And Europe Generic Injectable Market; 1.4 Limitations; 1.5 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Years Considered For The Study; 2.3 Currency And Pricing; 2.4 Dbmr Tripod Data Validation Model; 2.5 India Multivariate Modelling; 2.6 Type Lifeline Curve; 2.7 Primary Interviews With Key Opinion Leaders; 2.8 Vendor Share Analysis; 2.9 Secondary Sources; 2.10 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestal Analysis; 4.1.1 Europe; 4.1.2 India; 4.2 Porter Five Forced; 4.2.1 Europe; 4.2.2 India; 4.3 Epidemiology
5 Europe Generic Injecatble Market Overview: 5.1 Drivers; 5.1.1 Surge In Development And Production Of Generic Injectable; 5.1.2 Pioneering Progress Fueled By Technological Advancements In Drug Molecules; 5.1.3 Surge Of Generic Injectable Market Amidst The Escalating Prevalence Of Chronic Diseases 44; 5.2 Restraints; 5.2.1 Ensuring And Maintaining High-quality Standards; 5.2.2 Ensuring The Qualification And Ethical Standards Of A Contract Manufacturing Organization (Cmo); 5.2.3 Navigating Market Challenges In The Development Costs Of Generic Injectable; 5.3 Opportunities; 5.3.1 Ascendance Of Market Growth Through Increased Emphasis On Contract Research Manufacturing; 5.3.2 Synergizing Innovation Through Collaborative Drug Research And Development; 5.3.3 Expansion In Market Growth Fueled By Rising Preference For Generic Drugs Over Novel Alternatives; 5.3.4 Expanding Horizons Propelled By Growing Pipeline Of Innovative Products; 5.4 Challenges; 5.4.1 Logistical Challenges Due To Specialized Storage And Transportation Needs
6 India Generic Injecatble Market Overview: 6.1 Drivers; 6.1.1 Escalating Incidence Of Chronic Diseases; 6.1.2 Dependence On The Indian Manufacturers For Generic Version; 6.1.3 Availability Of A Wide Variety Of Distribution Channels; 6.2 Restraints; 6.2.1 Elevated Standards Of Quality Assurance In Generic Injectable; 6.3 Opportunities; 6.3.1 Market Expansion Surging With A Heightened Focus On Contract Research Manufacturing Organization; 6.3.2 Harmonizing Innovation By Collaborative Efforts In Drug Research And Development; 6.3.3 Market Growth Expands Due To Increasing Favor For Generic Drugs Instead Of Novel Alternatives; 6.3.4 Government Drive And Advocacy For Generic Medications; 6.4 Challenges; 6.4.1 Challenges In Logistics Arising From Specialized Storage And Transportation Requirements 61
7 India & Europe Injectable Drug Delivery Market, By Therapeutic Application: 7.1 Overview; 7.2 Oncology; 7.3 Cardiovascular Disorders; 7.4 Infectious Diseases; 7.5 Pain Management; 7.6 Metabolic Disorders (Diabetes); 7.7 Immunology Disorders
8 India & Europe Injectable Drug Delivery Market, By Biosimilar Drugs: 8.1 Overview; 8.2 Semaglutide; 8.3 Ibutilide Fumarate; 8.4 Evolocumab; 8.5 Alirocumab; 8.6 Anidulafungin; 8.7 Dulaglutide; 8.8 Lixisenatide; 8.9 Exenatide; 8.10 Liraglutide; 8.11 Adalimumab
9 India & Europe Injectable Drug Delivery Market, By End User: 9.1 Overview; 9.2 Direct Sales Distributors; 9.3 Pharmaceutical Wholesalers; 9.4 Drug Stores; 9.5 Pharmacy; 9.6 Group Purchasing Organizations (Gpos); 9.7 Others 95
10 India & Europe Injectable Drug Delivery Market, By Distribution Channel: 10.1 Overview; 10.2 Contract Manufacturers; 10.3 Pharmaceutical Wholesalers; 10.4 Pharmacy Chains; 10.5 Group Purchasing Organizations (Gpos); 10.6 Others
11 India And Europe Generic Injectable Market: Company Landscape: 11.1 Company Share Analysis: Europe; 11.2 Company Share Analysis: India
12 Swot Analysis: 12.1 Contract Manufacturers; 12.2 Manufacturers; 12.3 Distributors
13 Company Profile (Contract Manufacturers): 13.1 Boehringer Ingelheim International Gmbh; 13.1.1 Company Snapshot; 13.1.2 Product Portfolio; 13.1.3 Recent Development; 13.2 Cardinal Health; 13.2.1 Company Snapshot; 13.2.2 Revenue Analysis; 13.2.3 Product Portfolio; 13.2.4 Recent Development; 13.3 Divi's Laboratories Limited.; 13.3.1 Company Snapshot; 13.3.2 Revenue Analysis; 13.3.3 Product Portfolio; 13.3.4 Recent Development; 13.4 Dr. Reddy’s Laboratories Ltd; 13.4.1 Company Snapshot; 13.4.2 Revenue Analysis; 13.4.3 Product Portfolio; 13.4.4 Recent Development 116; 13.5 Fareva; 13.5.1 Company Snapshot; 13.5.2 Product Portfolio; 13.5.3 Recent Development; 13.6 Hikma Pharmaceuticals Plc; 13.6.1 Company Snapshot; 13.6.2 Revenue Analysis; 13.6.3 Product Portfolio; 13.6.4 Recent Developments; 13.7 Innovexia Lifesciences Pvt Ltd; 13.7.1 Company Snapshot; 13.7.2 Product Portfolio; 13.7.3 Recent Development; 13.8 Medlock Healthcare; 13.8.1 Company Snapshot; 13.8.2 Product Portfolio; 13.8.3 Recent Development; 13.9 Recipharm Ab.; 13.9.1 Company Snapshot; 13.9.2 Product Portfolio; 13.9.3 Recent Development; 13.10 Swisschem; 13.10.1 Company Snapshot; 13.10.2 Product Portfolio; 13.10.3 Recent Development; 13.11 Teva Pharmaceutical Industries Ltd; 13.11.1 Company Snapshot; 13.11.2 Revenue Analysis; 13.11.3 Product Portfolio; 13.11.4 Recent Development; 13.12 Venus Pharma Gmbh.; 13.12.1 Company Snapshot; 13.12.2 Product Portfolio; 13.12.3 Recent Development; 13.13 Zydus Group; 13.13.1 Company Snapshot; 13.13.2 Revenue Analysis; 13.13.3 Product Portfolio; 13.13.4 Recent Development 130
14 Company Profiles (Distributors): 14.1 Aah Pharmaceuticals Ltd; 14.1.1 Company Snapshot; 14.1.2 Product Description; 14.1.3 Recent Development; 14.2 Henry Schein, Inc.; 14.2.1 Company Snapshot; 14.2.2 Revenue Analysis; 14.2.3 Product Portfolio; 14.2.4 Recent Development; 14.3 Mawdsleys – Brooks & Co. Ltd.; 14.3.1 Company Snapshot; 14.3.2 Product Description; 14.3.3 Recent Development; 14.4 Medline Industries, Lp.; 14.4.1 Company Snapshot; 14.4.2 Product Portfolio; 14.4.3 Recent Development
15 Company Profiles (Generic Manufacturers): 15.1 Fresenius Se & Co. Kgaa; 15.1.1 Company Snapshot; 15.1.2 Revenue Analysis; 15.1.3 Product Portfolio; 15.1.4 Recent Development; 15.2 Amneal Pharmaceuticals Llc; 15.2.1 Company Snapshot; 15.2.2 Revenue Analysis; 15.2.3 Product Portfolio; 15.2.4 Recent Development; 15.3 Sun Pharmaceutical Industries Ltd.; 15.3.1 Company Snapshot; 15.3.2 Revenue Analysis; 15.3.3 Product Portfolio; 15.3.4 Recent Development; 15.4 Lupin.; 15.4.1 Company Snapshot; 15.4.2 Revenue Analysis; 15.4.3 Product Portfolio; 15.4.4 Recent Development; 15.5 Zydus Group; 15.5.1 Company Snapshot; 15.5.2 Revenue Analysis; 15.5.3 Product Portfolio; 15.5.4 Recent Development; 15.6 Aurobindo Pharma.; 15.6.1 Company Snapshot; 15.6.2 Revenue Analysis; 15.6.3 Product Portfolio; 15.6.4 Recent Developments; 15.7 Cipla Inc.; 15.7.1 Company Snapshot; 15.7.2 Revenue Analysis; 15.7.3 Product Portfolio; 15.7.4 Recent Developments; 15.8 Concord Biotech.; 15.8.1 Company Snapshot; 15.8.2 Revenue Analysis; 15.8.3 Product Portfolio; 15.8.4 Recent Development; 15.9 Dr. Reddy’s Laboratories Ltd; 15.9.1 Company Snapshot; 15.9.2 Revenue Analysis; 15.9.3 Product Portfolio; 15.9.4 Recent Development; 15.10 Gland Pharma Limited; 15.10.1 Company Snapshot; 15.10.2 Source: Company Website, Annual Reports, And Sec Filing; 15.10.3 Revenue Analysis; 15.10.4 Product Portfolio; 15.10.5 Recent Development; 15.11 Glenmark Pharmaceuticals Ltd; 15.11.1 Company Snapshot; 15.11.2 Revenue Analysis; 15.11.3 Product Portfolio; 15.11.4 Recent Development 160; 15.12 Hikma Pharmaceuticals Plc; 15.12.1 Company Snapshot; 15.12.2 Revenue Analysis; 15.12.3 Product Portfolio; 15.12.4 Recent Developments; 15.13 Intas Pharmaceuticals Ltd.; 15.13.1 Company Snapshot; 15.13.2 Product Portfolio; 15.13.3 Recent Development; 15.14 Par Pharmaceutical.; 15.14.1 Company Snapshot; 15.14.2 Product Portfolio; 15.14.3 Recent Development; 15.15 Sandoz Group Ag; 15.15.1 Company Snapshot; 15.15.2 Revenue Analysis; 15.15.3 Product Portfolio; 15.15.4 Recent Development; 15.16 Sanofi; 15.16.1 Company Snapshot; 15.16.2 Revenue Analysis; 15.16.3 Product Portfolio; 15.16.4 Recent Development; 15.17 Viatris Inc.; 15.17.1 Company Snapshot; 15.17.2 Revenue Analysis; 15.17.3 Product Portfolio; 15.17.4 Recent Development
16 Questionnaire
17 Related Reports
18 References
List Of Tables: Table 1 India Generic Injectable Market, By Therapeutic Application, 2022-2035 (Usd Million); Table 2 Europe Generic Injectable Market, By Therapeutic Application, 2022-2035 (Usd Million); Table 3 Europe Oncology In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 4 Europe Oncology In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 5 Europe Cardiovascular Disorders In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 6 India Cardiovascular Disorders In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 7 Europe Infectious Diseases In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 8 India Infectious Diseases In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 9 Europe Pain Management In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 10 India Pain Management In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 11 Europe Metabolic Disorders (Diabetes) In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 12 India Metabolic Disorders (Diabetes) In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 13 Europe Immunology In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 14 India Immunology In Generic Injectable Market, By Drugs, 2022-2035 (Usd Million); Table 15 Europe Generic Injectable Market, By Biosimilar Drugs, 2022-2035 (Usd Million); Table 16 India Generic Injectable Market, By Biosimilar Drugs, 2022-2035 (Usd Million); Table 17 Europe Generic Injectable Market, By End User, 2022-2035 (Usd Million); Table 18 India Generic Injectable Market, By End User, 2022-2035 (Usd Million); Table 19 Europe Generic Injectable Market, By End User, 2022-2035 (Usd Million); Table 20 India Generic Injectable Market, By End User, 2022-2035 (Usd Million); Table 21 Europe Generic Injectable Market, By Distribution Channel, 2022-2035 (Usd Million); Table 22 India Generic Injectable Market, By Distribution Channel, 2022-2035 (Usd Million)
List Of Figures: Figure 1 India And Europe Generic Injectable Market: Segmentation; Figure 2 India And Europe Generic Injectable Market: Data Triangulation; Figure 3 India Generic Injectable Market: Droc Analysis; Figure 4 Europe Generic Injectable Market: Droc Analysis; Figure 5 India Generic Injectable Market: Regional Vs Country Market Analysis; Figure 6 Europe Generic Injectable Market: Regional Vs Country Market Analysis; Figure 7 India And Europe Generic Injectable Market: Company Research Analysis; Figure 8 Europe Multivariate Modelling; Figure 9 India And Europe Generic Injectable Market: Interview Demographics; Figure 10 India And Europe Generic Injectable Market: Vendor Share Analysis; Figure 11 India And Europe Generic Injectable Market: Segmentation; Figure 12 Escalating Incidence Of Chronic Diseases And Surge In The Development And Production Of Generic Injectable Is Driving The Growth Of The India Generic Injectable Market In The Forecast Period Of 2024 To 2035; Figure 13 Surge In Development And Production Of Generic Injectable Drugs Is Expected To Drive The European Generic Injectable Market In The Forecast Period Of 2024 To 2035; Figure 14 Oncology Segment Is Expected To Account For The Largest Share Of The India Generic Injectable Market In 2024 And 2035; Figure 15 Oncology Segment Is Expected To Account For The Largest Share Of The Europe Generic Injectable Market In 2024 And 2035; Figure 16 Drivers, Restraints, Opportunities, And Challenges Of Europe Generic Injecatble Market; Figure 17 Drivers, Restraints, Opportunities And Challenges Of India Generic Injecatble Market; Figure 18 Europe Generic Injectable Market: By Therapeutic Application, 2023; Figure 19 Europe Generic Injectable Market: By Therapeutic Application, 2024-2035 (Usd Million); Figure 20 Europe Generic Injectable Market: By Therapeutic Application, Cagr (2024-2035); Figure 21 Europe Generic Injectable Market: By Therapeutic Application, Lifeline Curve; Figure 22 India Generic Injectable Market: By Therapeutic Application, 2023; Figure 23 India Generic Injectable Market: By Therapeutic Application, 2024-2035 (Usd Million); Figure 24 India Generic Injectable Market: By Therapeutic Application, Cagr (2024-2035); Figure 25 India Generic Injectable Market: By Therapeutic Application, Lifeline Curve; Figure 26 Europe Generic Injectable Market: By Biosimilar Drugs, 2023; Figure 27 Europe Generic Injectable Market: By Biosimilar Drugs, 2024-2035 (Usd Million); Figure 28 India Generic Injectable Market: By Biosimilar Drugs, 2023; Figure 29 India Generic Injectable Market: By Biosimilar Drugs, 2024-2035 (Usd Million); Figure 30 Europe Generic Injectable Market: By End User, 2023; Figure 31 Europe Generic Injectable Market: By End User, 2024-2035 (Usd Million); Figure 32 Europe Generic Injectable Market: By End User, Cagr (2024-2035); Figure 33 Europe Generic Injectable Market: By End User, Lifeline Curve; Figure 34 India Generic Injectable Market: By End User, 2023; Figure 35 India Generic Injectable Market: By End User, 2024-2035 (Usd Million); Figure 36 India Generic Injectable Market: By End User, Cagr (2024-2035); Figure 37 India Generic Injectable Market: By End User, Lifeline Curve; Figure 38 Europe Generic Injectable Market: By Distribution Channel, 2023; Figure 39 Europe Generic Injectable Market: By Distribution Channel, 2024-2035 (Usd Million); Figure 40 Europe Generic Injectable Market: By Distribution Channel, Cagr (2024-2035); Figure 41 Europe Generic Injectable Market: By Distribution Channel, Lifeline Curve; Figure 42 India Generic Injectable Market: By Distribution Channel, 2023; Figure 43 India Generic Injectable Market: By Distribution Channel, 2024-2035 (Usd Million); Figure 44 India Generic Injectable Market: By Distribution Channel, Cagr (2024-2035); Figure 45 India Generic Injectable Market: By Distribution Channel, Lifeline Curve; Figure 46 Europe Generic Injectable Market: Company Share 2023 (%); Figure 47 India Generic Injectable Market: Company Share 2023 (%)